Compounded semaglutide is not the same as Ozempic. While both products are intended to contain semaglutide as the active ingredient, they differ in how they’re manufactured, regulated, and delivered to patients. Ozempic is an FDA-approved, brand-name injection made exclusively by Novo Nordisk using a precise, clinically tested manufacturing process. Compounded semaglutide is mixed by individual pharmacies, has not undergone FDA review for safety or effectiveness, and may use different chemical forms of the molecule altogether.
What Makes Ozempic Different
Ozempic contains semaglutide base, a large peptide molecule with a specific molecular structure (molecular weight of 4,113.58 g/mol) produced through a yeast fermentation process. The molecule is engineered with several deliberate modifications: a fatty acid chain attached at one point to help it bind to a blood protein called albumin (which keeps it active in the body for about a week), and a chemical tweak at another point that prevents the body from breaking it down too quickly. These modifications are what make a once-weekly injection possible.
Ozempic is FDA-approved for two specific uses: improving blood sugar control in adults with type 2 diabetes, and reducing the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and established heart disease. Every batch goes through standardized quality controls before reaching patients, and the pre-filled pen is designed to deliver precise doses.
How Compounded Versions Differ
Compounded semaglutide is prepared by pharmacies that source bulk semaglutide powder and mix it into injectable solutions. The chemical form used in these products is often not the same as what’s in Ozempic. Some compounding pharmacies have used semaglutide sodium or semaglutide acetate, which are salt forms of the molecule. These salt forms have not been tested to confirm they work the same way in the body as the semaglutide base used in Ozempic.
Many compounders also add ingredients not found in the brand-name product, such as vitamin B-12, vitamin B-6, L-carnitine, or NAD. The safety and effectiveness of combining semaglutide with these additives has never been studied. There’s no clinical data showing these combinations are safe, let alone beneficial.
Testing conducted by Novo Nordisk on compounded samples found that some contained lower amounts of semaglutide than labeled, and some contained no semaglutide at all. The samples also frequently contained new impurities or higher levels of impurities compared to the branded product, none of which have been evaluated in clinical trials.
The Dosing Risk With Compounded Products
One of the most concrete safety differences is how the medication is delivered. Ozempic comes in a pre-filled, dial-a-dose pen that makes overdosing difficult. Compounded semaglutide typically comes in multi-dose vials, requiring patients to draw up their own dose using a syringe.
The FDA has received reports of patients being hospitalized after accidentally injecting five to 20 times the intended dose of compounded semaglutide. The errors stem from confusion between units of measurement: milliliters, milligrams, and “units” on insulin syringes all mean different things, and many patients receiving compounded semaglutide have no prior experience with self-injection. In one case, a patient was told to draw up a 5-unit dose using an insulin syringe but mistakenly administered 50 units. In another, a healthcare provider prescribed 25 units when they meant 0.25 milligrams (which equals 5 units), giving three patients ten times the intended dose.
Overdoses have caused severe nausea, vomiting, abdominal pain, fainting, dehydration, acute pancreatitis, and gallstones.
Why Compounded Semaglutide Exists
The market for compounded semaglutide grew during a period when Ozempic and Wegovy (the weight-loss version of semaglutide) were in shortage. Under federal law, pharmacies are allowed to compound drugs that are on the FDA’s official shortage list, even if those drugs are patented. This created a legal window for pharmacies to produce their own versions.
That window has narrowed. Semaglutide no longer appears on the FDA’s drug shortage list, which changes the legal landscape for compounders. Novo Nordisk, the sole manufacturer of all approved semaglutide products (Ozempic, Wegovy, and Rybelsus), has been taking legal action against compounders it considers to be operating outside the law, framing unauthorized compounding as a patient safety issue.
The Cost Factor
Price is the primary reason many people turn to compounded versions. Ozempic’s list price runs around $1,400 per month without insurance, while compounded semaglutide has been available for roughly $250 per month. For patients paying out of pocket, particularly those using semaglutide off-label for weight loss (which many insurers won’t cover), that difference is significant enough to drive demand regardless of the regulatory concerns.
Insurance plans that do cover Ozempic for type 2 diabetes typically will not cover a compounded alternative, since compounded drugs lack FDA approval. This creates a situation where patients with diabetes coverage may pay less for Ozempic than for a compounded version, while patients without coverage face the opposite math.
How to Evaluate a Compounding Pharmacy
If you’re considering a compounded product, the pharmacy’s credentials matter. Look for accreditation from the Pharmacy Compounding Accreditation Board (PCAB), which is the most widely recognized standard for compounding quality. PCAB-accredited pharmacies are evaluated against specific standards for both sterile compounding (relevant for injectables) and non-sterile preparations, covering the consistency and quality of what they produce.
Under federal law, a compounding pharmacy must fill compounded prescriptions based on a valid prescription from a licensed provider, for an identified individual patient. The pharmacy must use bulk drug substances from registered manufacturers, accompanied by certificates of analysis confirming what’s in the raw material. Pharmacies operating under Section 503A of federal law are traditional pharmacies filling individual prescriptions; those under Section 503B are outsourcing facilities that can produce larger batches but face additional FDA oversight.
Even with a reputable pharmacy, the fundamental difference remains: compounded semaglutide has not been through the FDA approval process, its specific formulation has not been tested in clinical trials, and its long-term effects in the forms being compounded are unknown. What you’re getting may contain the same active molecule as Ozempic, but the product as a whole is not equivalent.